Protox acquires research program from Medicenna

    VANCOUVER, Aug. 21 /CNW/ - Protox Therapeutics Inc. (TSX-V:PRX) announced
today that it has entered into an asset purchase agreement with Medicenna
Ventures Inc. ("Medicenna") for the acquisition of Medicenna's HUMxin(TM)
Program, a research program to develop fully humanized fusion proteins based
upon the Bcl-2 family, which are key components of programmed cell death
("apoptosis"). HUMxin represents a third technology platform for the Company
and offers the potential to develop targeted therapeutics for the treatment of
various diseases including solid tumors, metastases and hematological
malignancies. In addition, the technology may have application for the
treatment of neurodegenerative diseases, such as stroke, and has the potential
to protect and regenerate cells, tissues and organs following cancer treatment
or stem cell transplantation.
    "We are very pleased to have acquired this exciting technology platform
from Medicenna," said Dr. Fahar Merchant, President and Chief Executive
Officer of Protox. "The HUMxin platform is a natural extension of our existing
programs and further strengthens our core expertise in targeted delivery of
potent payloads for the treatment of several debilitating diseases that
currently lack adequate therapeutic options."
    Prior to joining Protox as President and Chief Executive Officer,
Dr. Merchant founded Medicenna and had worked with the U.S. National Institute
of Health ("NIH") to develop the HUMxin Program. Medicenna entered into a
Collaborative Research and Development Agreement ("CRADA") with the NIH
related to the HUMxin Program. Pursuant to the terms of the agreement,
Medicenna has transferred the HUMxin CRADA and all its rights and interests to
Protox and the Company has agreed to pay Medicenna $209,680 for its audited
out-of-pocket HUMxin CRADA and related expenses incurred to date. Half of this
amount will be paid to Medicenna in cash and the other half in the form of
127,854 common shares of the Company, which will be subject to a four month
hold period.

    About Protox

    Protox Therapeutics is a leader in advancing novel, targeted protein
toxin therapeutics for the treatment of cancer and other proliferative
diseases. The company is actively developing two distinct but complementary
platforms, INxin(TM) and PORxin(TM), and currently has four clinical programs
in development. A Phase IIa clinical trial into the use of PRX321 (INxin) for
the treatment of primary brain cancer has been completed and the drug has
received Fast Track Designation and Orphan Drug Status from the US FDA. In
addition, a Phase I trial has been completed for PRX321 to treat patients with
renal cell carcinoma and non-small cell lung cancer. Patient enrollment has
been completed for a Phase I clinical trial into the use of PRX302 (PORxin)
for the treatment of localized prostate cancer. A Phase I clinical study of
PRX302 for the treatment of benign prostatic hyperplasia (enlarged prostate)
is ongoing.


    Certain statements included in this press release may be considered
forward-looking. Such statements involve known and unknown risks,
uncertainties and other factors that may cause actual results, performance or
achievements to be materially different from those implied by such statements,
and therefore these statements should not be read as guarantees of future
performance or results. All forward-looking statements are based on Protox'
current beliefs as well as assumptions made by and information currently
available to Protox and relate to, among other things, anticipated financial
performance, business prospects, strategies, regulatory developments, market
acceptance and future commitments. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of the date
of this press release. Due to risks and uncertainties, including the risks and
uncertainties identified by Protox in its public securities filings; actual
events may differ materially from current expectations. Protox disclaims any
intention or obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise.

    %SEDAR: 00019575E

For further information:

For further information: James Beesley, Director, Investor Relations,
Protox Therapeutics, (604) 688-0199,; Michael
Moore, Investor Relations, Equicom Group, (416) 815-0700 x 241,

Organization Profile

Sophiris Bio, Inc.

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890